Phaseline

Companies › Sclnow Biotechnology

Sclnow Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Infectious disease, Other, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SCLnow 19# (Human umbilical cord mesenchymal stem cells)
Autologous/allogeneic mesenchymal stem cell therapy administered via intraarticular inject
–Phase 2Osteoarthritis, KneeDec 2026
human umbilical cord mesenchymal stem cells (19#iSCLife®-LDP)
Human umbilical cord mesenchymal stem cell therapy
–Phase 1Lumbar Discogenic Pain; Hepatitis BDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04104412human umbilical cord mesenchymal stem cells (19#iSCLife®-LDP)Phase 1Lumbar Discogenic PainOtherDec 2026
NCT03826433human umbilical cord mesenchymal stem cells (19#iSCLife®-LDP)Phase 1Hepatitis BInfectious diseaseDec 2026
NCT03383081SCLnow 19# (Human umbilical cord mesenchymal stem cells)Phase 2Osteoarthritis, KneeImmunologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

InventVacc Biologicals Medipost Aimei Vacin BioPharm (Zhejiang) Sirnaomics Changchun BCHT Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.